USANA Health Sciences (NYSE:USNA) Releases FY 2025 Earnings Guidance

USANA Health Sciences (NYSE:USNA - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.350-3.000 for the period, compared to the consensus earnings per share estimate of 2.610. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $947.0 million.

USANA Health Sciences Price Performance

Shares of NYSE:USNA traded down $0.13 during midday trading on Friday, reaching $31.97. The company's stock had a trading volume of 175,530 shares, compared to its average volume of 137,350. USANA Health Sciences has a fifty-two week low of $23.10 and a fifty-two week high of $45.86. The company has a market capitalization of $595.19 million, a P/E ratio of 17.76, a P/E/G ratio of 1.02 and a beta of 0.64. The business's fifty day simple moving average is $30.86 and its 200-day simple moving average is $30.11.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.20. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. The company had revenue of $235.85 million during the quarter, compared to analyst estimates of $225.20 million. On average, analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd.

Insider Activity

In other USANA Health Sciences news, CFO G Doug Iiekking sold 4,548 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Walter Noot sold 6,291 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total value of $190,554.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,013 shares of company stock worth $360,149. 0.63% of the stock is owned by company insiders.

Hedge Funds Weigh In On USANA Health Sciences

A hedge fund recently raised its stake in USANA Health Sciences stock. AQR Capital Management LLC increased its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 82.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,845 shares of the company's stock after purchasing an additional 9,894 shares during the period. AQR Capital Management LLC owned approximately 0.12% of USANA Health Sciences worth $589,000 at the end of the most recent quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.